FY2023 EPS Estimates for Hookipa Pharma Inc Raised by Analyst (NASDAQ:HOOK)

Hookipa Pharma Inc (NASDAQ:HOOKFree Report) – Leerink Partnrs increased their FY2023 earnings estimates for shares of Hookipa Pharma in a report released on Monday, February 5th. Leerink Partnrs analyst A. Berens now anticipates that the company will post earnings of ($0.66) per share for the year, up from their previous estimate of ($0.85). The consensus estimate for Hookipa Pharma’s current full-year earnings is ($0.87) per share. Leerink Partnrs also issued estimates for Hookipa Pharma’s Q1 2024 earnings at ($0.06) EPS, Q2 2024 earnings at ($0.06) EPS, Q3 2024 earnings at ($0.06) EPS, Q4 2024 earnings at ($0.06) EPS, FY2024 earnings at ($0.24) EPS, FY2025 earnings at ($0.36) EPS and FY2026 earnings at ($0.42) EPS.

Hookipa Pharma (NASDAQ:HOOKGet Free Report) last released its earnings results on Thursday, November 9th. The company reported ($0.17) EPS for the quarter, topping the consensus estimate of ($0.23) by $0.06. The firm had revenue of $6.87 million during the quarter, compared to analysts’ expectations of $3.39 million. Hookipa Pharma had a negative net margin of 336.12% and a negative return on equity of 70.24%.

Separately, Royal Bank of Canada decreased their price target on shares of Hookipa Pharma from $6.00 to $5.00 and set an “outperform” rating on the stock in a report on Tuesday, January 30th.

Check Out Our Latest Stock Analysis on HOOK

Hookipa Pharma Price Performance

HOOK stock opened at $0.67 on Thursday. Hookipa Pharma has a one year low of $0.41 and a one year high of $2.05. The company has a 50 day moving average price of $0.69 and a two-hundred day moving average price of $0.63.

Hedge Funds Weigh In On Hookipa Pharma

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Artal Group S.A. lifted its holdings in shares of Hookipa Pharma by 206.4% during the 2nd quarter. Artal Group S.A. now owns 5,666,410 shares of the company’s stock valued at $4,986,000 after acquiring an additional 3,816,794 shares in the last quarter. Knoll Capital Management LLC lifted its holdings in shares of Hookipa Pharma by 1,739.1% during the 2nd quarter. Knoll Capital Management LLC now owns 5,517,385 shares of the company’s stock valued at $4,855,000 after acquiring an additional 5,217,385 shares in the last quarter. Vanguard Group Inc. increased its stake in Hookipa Pharma by 6.8% during the 3rd quarter. Vanguard Group Inc. now owns 1,763,621 shares of the company’s stock worth $2,364,000 after buying an additional 111,890 shares during the period. Walleye Capital LLC purchased a new stake in Hookipa Pharma during the 2nd quarter worth $1,008,000. Finally, Jefferies Financial Group Inc. purchased a new stake in Hookipa Pharma during the 4th quarter worth $849,000. Institutional investors and hedge funds own 83.02% of the company’s stock.

Hookipa Pharma Company Profile

(Get Free Report)

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.

See Also

Earnings History and Estimates for Hookipa Pharma (NASDAQ:HOOK)

Receive News & Ratings for Hookipa Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hookipa Pharma and related companies with MarketBeat.com's FREE daily email newsletter.